Overall survival | Progression-free survival | |||||||||||
Parameter | Univariate Cox regression | Multivariate regression | Univariate regression | Multivariate regression | ||||||||
HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | |
LIPS signature | ||||||||||||
High risk | Ref | Ref | Ref | Ref | ||||||||
Low risk | 0.28 | 0.15 to 0.52 | <0.001*** | 0.27 | 0.13 to 0.59 | <0.001*** | 0.22 | 0.12 to 0.39 | <0.001*** | 0.24 | 0.11 to 0.55 | <0.001*** |
Age | ||||||||||||
<60 years | Ref | Ref | Ref | Ref | ||||||||
≥60 years | 1.36 | 0.77 to 2.41 | 0.3 | 2.27 | 1.14 to 4.53 | 0.02* | 1.13 | 0.68 to 1.86 | 0.6 | 1.58 | 0.89 to 2.80 | 0.12 |
Gender | ||||||||||||
Male | Ref | Ref | Ref | Ref | ||||||||
Female | 1 | 0.54 to 1.86 | 1 | 1.48 | 0.70 to 3.15 | 0.305 | 0.77 | 0.44 to 1.34 | 0.4 | 0.99 | 0.52 to 1.88 | 0.98 |
Tumor entity | ||||||||||||
Others | Ref | Ref | Ref | Ref | ||||||||
HNSCC | 0.91 | 0.54 to 1.55 | 0.7 | 0.51 | 0.21 to 1.25 | 0.142 | 1.41 | 0.88 to 2.25 | 0.1 | 0.80 | 0.34 to 1.89 | 0.618 |
NSCLC | 0.94 | 0.56 to 1.59 | 0.8 | 0.56 | 0.23 to 1.40 | 0.216 | 0.7 | 0.44 to 1.12 | 0.1 | 0.55 | 0.22 to 1.36 | 0.20 |
Brain metastases | ||||||||||||
Yes | Ref | Ref | Ref | Ref | ||||||||
No | 0.43 | 0.24 to 0.79 | 0.005** | 0.56 | 0.27 to 1.17 | 0.123 | 0.46 | 0.26 to 0.80 | 0.005** | 0.85 | 0.39 to 1.89 | 0.698 |
PD-L1 TPS | ||||||||||||
<1 %/NA | Ref | Ref | Ref | Ref | ||||||||
1%–49% | 0.69 | 0.39 to 1.24 | 0.2 | 0.61 | 0.31 to 1.22 | 0.162 | 0.61 | 0.36 to 1.02 | 0.06 | 0.57 | 0.30 to 1.10 | 0.093 |
50%–100% | 0.78 | 0.43 to 1.41 | 0.4 | 0.45 | 0.21 to 0.95 | 0.037* | 0.89 | 0.54 to 1.47 | 0.6 | 0.63 | 0.32 to 1.21 | 0.165 |
Number of previous treatments | ||||||||||||
≥2 | Ref | Ref | Ref | Ref | ||||||||
0–1 | 0.60 | 0.34 to 1.08 | 0.08 | 0.79 | 0.39 to 1.59 | 0.508 | 0.49 | 0.30 to 0.82 | 0.005** | 0.63 | 0.36 to 1.11 | 0.111 |
*p<0.05, **p<0.01, ***p<0.001.
HNSCC, head and neck squamous cell carcinoma; LIPS, liquid immune profile-based signature; NSCLC, non-small cell lung cancer; TPS, tumor proportion score.